Cite
HARVARD Citation
Hari, P. et al. (2019). Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Leukemia research. p. . [Online].